Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination
Regina Célia de Souza Campos Fernandes,
Daniela Vieira Nunes,
Nathália Fragoso de Almeida,
Nathalia da Cruz Assad Monteiro,
Luiza Amanda Maron Pimenta,
Enrique Medina-Acosta
Affiliations
Regina Célia de Souza Campos Fernandes
Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil; Universidade Estadual do Norte Fluminense, Avenida Alberto Lamego 2000, Campos dos Goytacazes, Rio de Janeiro, CEP 28013-602, Brazil
Daniela Vieira Nunes
Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil
Nathália Fragoso de Almeida
Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil
Nathalia da Cruz Assad Monteiro
Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil
Luiza Amanda Maron Pimenta
Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil
Enrique Medina-Acosta
Universidade Estadual do Norte Fluminense, Avenida Alberto Lamego 2000, Campos dos Goytacazes, Rio de Janeiro, CEP 28013-602, Brazil; Corresponding author at: Universidade Estadual do Norte Fluminense, Laboratório de Biotecnologia, Avenida Alberto Lamego 2000, Parque Califórnia, Campos dos Goytacazes, RJ, CEP 28013-602 Brazil.
The COVID-19 pandemic has significantly impacted global health, and the widespread immunization of adults against SARS-CoV-2 has played a pivotal role in altering the course of the disease. While COVID-19 vaccine adverse events are generally uncommon and mild, the recent vaccination of the pediatric population has emphasized the need for vigilance and reporting of potential side effects. In this case report, we present a 6-year-old boy who developed Henoch-Schönlein purpura following the administration of the first dose of Pfizer-BioNTech BNT16B2b2 mRNA COVID-19 vaccine, making it the earliest reported case of such an adverse event. Our report highlights the importance of continued monitoring and reporting of adverse events in pediatric patients receiving the COVID-19 vaccine, as well as the need for prompt diagnosis and management of potential vaccine-related complications.
